A spokesperson for Novartis confirmed the report in a statement emailed to Fierce Pharma. In a move that was effective in February, Novartis Gene Therapies was broken up and integrated into the company, costing nearly 150 employees their jobs, Endpoints reported on Tuesday.
It was with similar stealth that the unit Lennon formerly headed up fell victim to a reorganization by the company. Two months ago, Novartis Gene Therapies chief Dave Lennon left the company to lead a biotech startup that is operating in stealth mode.
